Novo Nordisk Option Alert: Sep 19 $50 Puts at the Bid: 3000 vs 7667 OI

Novo Nordisk Option Alert: Sep 19 $50 Puts at the Bid: 3000 @ $2.61 vs 7667 OI; Ref=$50.54

Novo Nordisk Option Alert: Jun 18 $70 Calls at the Bid: 9998 vs 2079 OI; Earnings 8/6 Before Open 

Novo Nordisk Option Alert: Jun 18 $70 Calls at the Bid: 9998 @ $2.1 vs 2079 OI; Earnings 8/6 Before Open Ref=$45.56

Novo Nordisk Option Alert: Jan 16 $40 Puts at the Bid: 4000 vs 4155 OI; Earnings 8/15 Before Open [est] 

Novo Nordisk Option Alert: Jan 16 $40 Puts at the Bid: 4000 @ $1.9 vs 4155 OI; Earnings 8/15 Before Open [est] Ref=$49.05

Novo Nordisk Option Alert: Mar 20 $45 Puts at the Bid: 1250 vs 3749 OI; Earnings 8/15 Before Open [est] 

Novo Nordisk Option Alert: Mar 20 $45 Puts at the Bid: 1250 @ $4.26 vs 3749 OI; Earnings 8/15 Before Open [est] Ref=$48.685

Novo Nordisk Option Alert: Jan, 2027 $75 Puts at the Bid: 2500 vs 4057 OI; Earnings 8/15 Before Open [est] 

Novo Nordisk Option Alert: Jan, 2027 $75 Puts at the Bid: 2500 @ $28.2 vs 4057 OI; Earnings 8/15 Before Open [est] Ref=$48.695

Novo Nordisk

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Konskie,,Poland,-,January,11,,2024:,Novo,Nordisk,Pharmaceutical,Company

Equities

Le azioni di Novo Nordisk guadagnano terreno dopo il flop di Eli Lilly, consolidando la sua posizione nel mercato dei farmaci dimagranti.

Farmaci per perdere peso: il titolo Novo Nordisk sale nel pre-market

Eli Lilly

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Movers

General

Il titolo soffre per EPS sotto le attese e competizione crescente nel settore farmaceutico, nonostante ricavi e utili in crescita.

Crollo Eli Lilly: il produttore del farmaco dimagrante in difficoltà

Weight,Loss,Injection,Pen,-,Mounjaro,Injection,Pen,,Medicines,To

Trading Ideas

Trial cardiovascolare da 13.000 pazienti mostra risultati promettenti, ma Wall Street reagisce con vendite. Analisi dati e impatti.

Eli Lilly: nuovo studio su Mounjaro supera le aspettative, ma il titolo crolla

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

Legal

Press Releases

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO

NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Fir

Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

LINE

NOVO

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Merck & Co

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
11:13 AMAug 08, 2025	PUT	$50.00	Sep 19, 2025	38	231	3000	3	7667	TRADE	BULLISH
11:44 AMAug 06, 2025	CALL	$70.00	Jun 18, 2026	310	10052	9998	484	2079	TRADE	BEARISH
02:48 PMAug 04, 2025	PUT	$40.00	Jan 16, 2026	157	4140	4000	100	4155	TRADE	BEARISH
01:06 PMAug 04, 2025	PUT	$45.00	Mar 20, 2026	220	1312	1250	35	3749	TRADE	NEUTRAL
12:14 PMAug 04, 2025	PUT	$75.00	Jan 15, 2027	521	1	2500	0	4057	TRADE	BULLISH

Comments

Novo Nordisk

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO